KRAS and neoplasm: Recently, studies exploring the correlation between KRAS mutational status in primary and metastatic tumors of CRC patients revealed intra-tumor heterogeneity or mutation discordance after anti-EGFR treatment failure in patients with wild type KRAS [18–21].